A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2018
At a glance
- Drugs Atezolizumab (Primary) ; PRS 343 (Primary)
- Indications Bladder cancer; Breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Pieris Pharmaceuticals
- 07 Nov 2018 According to a Pieris Pharmaceuticals media release, Company intends to report data from this trial in 2019.
- 04 Sep 2018 According to a Pieris Pharmaceuticals media release, first patient has been dosed in the trial. The company expects to report findings from the study next year.
- 27 Aug 2018 Status changed from planning to recruiting.